Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study

Further Publications

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

Clin Cancer Res

Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA, Cordas Dos Santos DM, Rejeski K

doi: 10.1158/1078-0432.CCR-24-1798

Lymphoma

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

Blood Cancer J

Dulobdas V, Kirkwood AA, Serpenti F, Gautama B, Panopoulou A, Mathew A, Gabriel S, Malladi R, Pealing J, Bonney D, Nicholson E, Besley C, Ghorashian S, Kuhnl A, Davies E, Chappell J, Black A, Menne T, O'Reilly MA, Sanderson R, Chaganti S

doi: 10.1038/s41408-025-01225-9

Further Publications

Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies

Lancet Oncol

Khatsuria F, McMullan C, Aiyegbusi OL, Shaw KL, Iqbal R, Kinsella F, Wilson K, Pyatt L, Lewis M, Wheldon SMR, Burns D, Chakraverty R, Calvert M, Hughes SE

doi: 10.1016/S1470-2045(24)00256-0

Lymphoma

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell Lymphoma

Clin Cancer Res

Jhaveri K, Thapa R, Ercan D, Saha A, Noble J, Singh P, Fahrmann J, Saini N, Wu R, Dennison JB, Hanash S, Jenq RR, Modi K, Figura N, Chavez J, Shah B, Nishihori T, Lazaryan A, Khimani F, Bachmeier C, Gage K, Mishra A, Perna F, Davila ML, Spiegel J, Rejeski K, Subklewe M, Locke FL, Freeman C, Parker N, Jain MD

doi: 10.1158/1078-0432.CCR-24-3782

Multiple Myeloma (MM)

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

Br J Haematol

Zhou X, Wagner V, Scheller L, Stanojkovska E, Riedhammer C, Xiao X, Steinhardt MJ, Vogt C, Nerreter S, Eisele F, John M, Munawar U, Kadel SK, Mersi J, Ruckdeschel A, Schimanski S, Haertle L, Waldschmidt JM, Han S, Topp M, Duell J, Einsele H, Riedel A, Kortüm KM, Rasche L

doi: 10.1111/bjh.19515

Lymphoma

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Br J Haematol

de la Iglesia-San Sebastián I, López-Esteban M, Bastos-Oreiro M, Fernández de Córdoba-Oñate S, Gutierrez M, Carbonell D, Bailén R, Gómez-Centurión I, Fernández-Caldas P, Castilla L, Anguita J, Kwon M, García-Sanz R, Buño I, Martínez-Laperche C

doi: 10.1111/bjh.19916

Lymphoma

Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Am J Hematol

Tun AM, Patel RD, St-Pierre F, Ouchveridze E, Niu A, Thordardottir T, Obasi J, Rosenthal A, Pophali PA, Fenske TS, Karmali R, Ahmed S, Johnston PB

doi: 10.1002/ajh.27381

Lymphoma

Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma

Haematologica

Benjamini O, Fried S, Shouval R, Flynn JR, Beyar-Katz O, Leslie LA, Zucherman T, Yerushalmi R, Shem-Tov N, Palomba ML, Danylesko I, Sdayoor I, Malka H, Itzhaki O, Suh H, Devlin SM, Marcus R, Dahi PB, Jacoby E, Shah GL, Sauter CS, Ip A, Perales MA, Nagler A, Shimoni A, Scordo M, Avigdor A

doi: 10.3324/haematol.2023.284664

Lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Blood Cancer J

Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen L

doi: 10.1038/s41408-024-01195-4

Related content

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell Lymphoma

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma